Durable Effect of Imeglimin on the Glycemic Control in Patients With Type 2 Diabetes Mellitus
Status:
Recruiting
Trial end date:
2027-03-31
Target enrollment:
Participant gender:
Summary
Study subjects will be randomly assigned to the three groups and receive the study drug for
maximum of 156 weeks and undergo blood samplings and other diabetes mellitus-related tests.
The aim of the present study is to evaluate the durability of glycemic control over 3 years
for patients with type 2 diabetes on diet and exercise therapy treated with oral hypoglycemic
drug monotherapy.
Phase:
Phase 4
Details
Lead Sponsor:
National Center for Global Health and Medicine, Japan